<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0003674'>Oxidative stress</z:mp> (OS) is involved in several human diseases, including <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, as well as <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We previously found that OS occurs in <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down Syndrome</z:e> as well as in <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann Syndrome</z:e> (BWS) </plain></SENT>
<SENT sid="2" pm="."><plain>Here we describe the clinical case of a female patient with Prader Willi Syndrome (PWS), a <z:mp ids='MP_0003121'>genomic imprinting</z:mp> disorder, characterized by <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> type 2, pathologies in which a continuous and important production of free radicals takes place </plain></SENT>
<SENT sid="3" pm="."><plain>We verified the presence of OS by measuring a redox biomarkers profile including total <z:chebi fb="0" ids="35923,35924">hydroperoxides</z:chebi> (TH), non protein-bound iron (NPBI), <z:chebi fb="0" ids="29256">thiols</z:chebi> (SH), advanced oxidation protein products (AOPP) and isoprostanes (IPs) </plain></SENT>
<SENT sid="4" pm="."><plain>Thus we introduced in therapy an <z:chebi fb="11" ids="22586">antioxidant</z:chebi> agent, namely <z:chebi fb="120" ids="26216">potassium</z:chebi> <z:chebi fb="0" ids="22651">ascorbate</z:chebi> with <z:chebi fb="1" ids="33942">ribose</z:chebi> (PAR), in addition to GH therapy and we monitored the redox biomarkers profile for four years </plain></SENT>
<SENT sid="5" pm="."><plain>A progressive decrease in OS biomarkers occurred until their normalization </plain></SENT>
<SENT sid="6" pm="."><plain>In the meantime a <z:hpo ids='HP_0001824'>weight loss</z:hpo> was observed together with a steady growth in standards for age and sex </plain></SENT>
</text></document>